Arno Therapeutics(OTC) ARNI

Arno Therapeutics, Inc. is a biopharmaceutical company based in Flemington, New Jersey, dedicated to developing innovative treatments for cancer and other serious health conditions. The company is advancing several promising compounds through various stages of clinical trials.

Products and Services

• Onapristone: A type 1 anti-progestin hormone blocker in Phase I/II trials for solid tumors
• AR-12: An oral cancer therapy that has completed Phase I studies for solid tumors and hematological malignancies
• AR-42: An oral treatment involved in a Phase I study targeting hematological malignancies and solid tumors

Growth Outlook

• Onapristone shows potential for treating advanced prostate and breast cancers
• AR-12 is in pre-clinical development for various microbial targets
• Partnerships with universities and pharmaceutical companies enhance research capabilities

Financial Highlights

• Recent quarterly net income reported at -$3.85 million
• Cash and cash equivalents increased to $2.12 million in Q3 2016
• Operating expenses totaled $2.23 million in the latest quarter

Arno Therapeutics, Inc. is positioned in the biotechnology sector, focusing on the development of therapies that address significant unmet medical needs. The company's lead product, Onapristone, is currently undergoing clinical trials, which could pave the way for new treatment options in oncology. The ongoing development of AR-12 and AR-42 further diversifies the company's portfolio, potentially leading to multiple revenue streams in the future. The financial data indicates a challenging environment, with substantial operating losses reported in recent quarters. However, the increase in cash reserves suggests a focus on sustaining operations and funding ongoing research. The partnerships established with academic institutions and other pharmaceutical entities may provide additional resources and expertise, enhancing the company's ability to innovate and bring new therapies to market. Overall, Arno Therapeutics, Inc. represents a speculative investment opportunity within the biotechnology space, driven by its commitment to developing novel cancer therapies and its strategic collaborations.